Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
09:29:56 EDT Sat 20 Apr 2024
Enter Symbol
or Name
USA
CA



Q:OCGN - OCUGEN INC - https://ocugen.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
OCGN - Q0.51.32·1.330.51.326,612.88,1298,9721.29  1.37  1.272.105  0.34519:55:2807:1315 min RT 2¢

Recent Trades - Last 10 of 8972
Time ETExPriceChangeVolume
19:55:28Q1.30-0.026
19:53:36Q1.32970.00971
19:52:39Q1.30-0.0220
19:51:57Q1.330.015
19:51:47Q1.330.0135
19:49:44Q1.330.0113,868
19:46:56Q1.330.016
19:46:20Q1.32 2
19:43:06Q1.31-0.01278
19:40:29Q1.31-0.0133

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-19 07:13U:OCGNNews ReleaseOcugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410-A Modifier Gene Therapy
2024-04-12 07:31U:OCGNNews ReleaseOcugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
2024-04-10 07:02U:OCGNNews ReleaseOcugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400-Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
2024-04-08 06:31U:OCGNNews ReleaseOcugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial - First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
2024-04-05 07:02U:OCGNNews ReleaseOcugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410-a Modifier Gene Therapy-in Phase 1/2 ArMaDa Study for Geographic Atrophy
2024-04-02 08:01U:OCGNNews ReleaseOcugen Provides Business Update with Certain Financials for the Year Ending 2023
2024-04-01 18:09U:OCGNNews ReleaseOcugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST-a Modifier Gene Therapy-in GARDian Study for Stargardt Disease
2024-04-01 17:44U:OCGNNews ReleaseOcugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
2024-03-18 06:31U:OCGNNews ReleaseOcugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
2024-03-13 08:01U:OCGNNews ReleaseOcugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
2024-03-06 07:30U:OCGNNews ReleaseOcugen to Present at Investing in Cures Summit
2024-02-28 08:00U:OCGNNews ReleaseOcugen Clinical Showcase Webcast Now Available
2024-02-26 08:30U:OCGNNews ReleaseOcugen Chairman and CEO to present at Abu Dhabi Family Office Summit
2024-02-22 16:05U:OCGNNews ReleaseOcugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
2024-02-21 16:05U:OCGNNews ReleaseOcugen to Present at 2024 BIO CEO & Investor Conference
2024-02-14 07:31U:OCGNNews ReleaseOcugen to Host Clinical Showcase in New York City on ‚  Wednesday, February 21, 2024
2024-01-31 08:00U:OCGNNews ReleaseOcugen to Present at Pharma Market Research Conference
2024-01-16 07:31U:OCGNNews ReleaseOcugen, Inc. Announces Bob Smith Joins Business Advisory Board
2023-12-21 06:30U:OCGNNews ReleaseOcugen Gains FDA Alignment on Key Aspects of OCU400 ¢ € ”Modifier Gene Therapy ¢ € ”Pivotal Phase 3 Study Design
2023-12-19 07:30U:OCGNNews ReleaseOcugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations